Notoginsenoside R1 CAS 80418-24-2

Introduction：Basic information about Notoginsenoside R1 CAS 80418-24-2, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.

Notoginsenoside R1 Basic information

• Product Name: Notoginsenoside R1
• Synonyms: (3β,6α,12β)-20-(β-D-Glucopyranosyloxy)-3,12-dihydroxydammar-24-en-6-yl 2-O-β-D-xylopyranosyl-β-D-glucopyranoside;Notoginsenoside Fb;NOTOGINSENOSIDE R1;NOTOGINSENOSIDE R1(SH);NOTOGINSENOSIDE;glucopyranosyloxy)-3,12-dihydroxydammar-24-en-6-yl2-O-β-D-xylopyranosyl-;Sanchinoside R1;Notoginsenoside R1，Sanchinoside R1
• CAS: 80418-24-2
• MF: C47H80O18
• MW: 933.14
• EINECS: 208-517-5
• Product Categories: chemical reagent;Inhibitors;pharmaceutical intermediate;phytochemical;reference standards from Chinese medicinal herbs (TCM).;standardized herbal extract
• Mol File: 80418-24-2.mol

Notoginsenoside R1 Chemical Properties

• Melting point: 215～217℃
• Boiling point: 1010.5±65.0 °C(Predicted)
• density: 1.39±0.1 g/cm3(Predicted)
• storage temp.: Sealed in dry,Room Temperature
• solubility: H2O: soluble1mg/mL, clear, colorless
• pka: 12.85±0.70(Predicted)
• form: powder
• color: white to off-white
• biological source: Panax notoginseng (Burk.) F.H.Chen
• Water Solubility: H2O: 1mg/mL, clear, colorless
• Major Application: metabolomics vitamins, nutraceuticals, and natural products
• InChIKey: LLPWNQMSUYAGQI-OOSPGMBYSA-N
• LogP: 1.354 (est)

Safety Information

• Hazard Codes: Xn
• Risk Statements: 22
• Safety Statements: 24/25
• WGK Germany: 3
• HS Code: 29389090
• Storage Class: 11 - Combustible Solids
• Hazard Classifications: Acute Tox. 4 Oral
• Hazardous Substances Data: 80418-24-2(Hazardous Substances Data)

Notoginsenoside R1 Usage And Synthesis

Description

Notoginsenoside R1 is a ginsenoside found in Panax notoginseng that is dammarane which is substituted by hydroxy groups at the 3beta, 6alpha, 12beta and 20 pro-S positions, in which the hydroxy groups at positions 6 and 20 have been converted to the corresponding beta-D-xylopyranosyl-(1->2)-beta-D-glucopyranoside and beta-D-glucopyranoside respectively, and in which a double bond has been introduced at the 24-25 position. It is a beta-D-glucoside, a 12beta-hydroxy steroid, a 3beta-hydroxy steroid, a disaccharide derivative, a ginsenoside, a tetracyclic triterpenoid and a 3beta-hydroxy-4,4-dimethylsteroid. It derives from a hydride of a dammarane.

Uses

Notoginsenoside R1 is an active ingredient isolated from Panax notoginseng that induces tissue-type plasminogen activator synthesis in cultured human umbilical vein endothelial cells.

Application

Notoginsenoside R1 has a role as a plant metabolite, an antioxidant, a neuroprotective agent, an apoptosis inducer and a phytoestrogen. 

Chemical Properties

Derived from the dried root of Panax ginseng of the Araliaceae family

Uses

Notoginsenoside R1 acts as an anti-inflammatory agent, inhibiting TNF-α induced PAI-1 production in aortic smooth muscle cells in humans.

Definition

ChEBI: Notoginsenoside R1 is a ginsenoside found in Panax notoginseng that is dammarane which is substituted by hydroxy groups at the 3beta, 6alpha, 12beta and 20 pro-S positions, in which the hydroxy groups at positions 6 and 20 have been converted to the corresponding beta-D-xylopyranosyl-(1->2)-beta-D-glucopyranoside and beta-D-glucopyranoside respectively, and in which a double bond has been introduced at the 24-25 position. It has a role as a plant metabolite, an antioxidant, a neuroprotective agent, an apoptosis inducer and a phytoestrogen. It is a beta-D-glucoside, a 12beta-hydroxy steroid, a 3beta-hydroxy steroid, a disaccharide derivative, a ginsenoside, a tetracyclic triterpenoid and a 3beta-hydroxy-4,4-dimethylsteroid. It derives from a hydride of a dammarane.

Biological Activity

Notoginsenoside R1 has been shown to exhibit antooxidant, anti-inflammatory, antiapoptotic, and immune-stimulatory properties.

in vivo

Notoginsenoside R1 (5 mg/kg/h; infused via the right jugular vein) increases red blood cell velocity, reduces the number of adherent leukocytes and inhibits mast cell degranulation and cytokine elevation in rats^[3].

• Animal Model: Male Sprague-Dawley (SD) rats (200-250 g)^[3]
• Dosage: 5 mg/kg/h
• Administration: Infused 20 min before LPS infusion via the right jugular vein
• Result: Ameliorated the LPS-induced reduction in the mesenteric venular shear rate to some extent. Attenuated the LPS-induced adhesion of leukocytes to the venular wall. Inhibited mast cell degranulation and cytokine elevation.